Review
Oncology
Bradley McGregor, Amir Mortazavi, Lisa Cordes, Cristina Salabao, Susan Vandlik, Andrea B. Apolo
Summary: Tyrosine kinase inhibitors combined with immune checkpoint inhibitors have been effective in treating advanced renal cell carcinoma. However, the overlapping adverse events and immune-related adverse events can complicate treatment, necessitating proper management strategies to maintain tolerability.
CANCER TREATMENT REVIEWS
(2022)
Article
Nursing
Asal Hafezi, Atye Babaii, Bahman Aghaie, Mohammad Abbasinia
Summary: This study aimed to investigate the associations between nurses' perceptions of patient safety culture, patient safety competency, and adverse events (AEs). The results showed that medication errors, pressure ulcers, falls, and the use of restraints were significantly associated with certain dimensions of patient safety culture and patient safety competency.
Article
Oncology
Dong-Yi Chen, Jia-Rou Liu, Chi-Nan Tseng, Ming-Jer Hsieh, Cheng-Keng Chuang, See-Tong Pang, Shao-Wei Chen, I-Chang Hsieh, Pao-Hsien Chu, Jen-Shi Chen, John Wen-Cheng Chang, Wen-Kuan Huang, Lai-Chu See
Summary: This study compared the risk for major adverse cardiovascular events (MACE) between targeted therapy and cytokine treatment in patients with advanced renal cell carcinoma (RCC). The results showed that the risk for MACE was higher in patients receiving targeted therapy compared to those receiving cytokine treatment.
JACC: CARDIOONCOLOGY
(2022)
Article
Medicine, General & Internal
Shuo-Yan Gau, Sung-Lang Chen, Cheng-Siu Chang, Teng-Fu Tsao, Jeng-Dau Tsai
Summary: This study investigated the adverse events of everolimus usage in patients with tuberous sclerosis complex (TSC) and found that TSC patients using everolimus are more likely to develop gingivostomatitis and proteinuria compared to nonusers.
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
(2023)
Review
Biochemistry & Molecular Biology
Husayn Ahmed Pallikonda, Samra Turajlic
Summary: This article reviews current approaches for evaluating the evolutionary features of cancer and discusses the impact of tumor sampling methods and experimental design. Using clear-cell renal cell carcinoma (ccRCC) as an example, the study explores the understanding and prediction of cancer evolutionary dynamics. Finally, the authors discuss the benefits of understanding cancer evolution for patients.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
(2022)
Article
Oncology
Xinan Sheng, DingWei Ye, Aiping Zhou, Xin Yao, Hong Luo, Zhisong He, Zengjun Wang, Yingchao Zhao, Zhigang Ji, Qing Zou, Chaohong He, Jianming Guo, Xinhua Tu, Ziling Liu, Benkang Shi, Ben Liu, Peng Chen, Qiang Wei, Zhiquan Hu, Yanqiao Zhang, Kui Jiang, Fangjian Zhou, Dapeng Wu, Cheng Fu, Xingya Li, Bin Wu, Lijie Wang, Shukui Qin, Gang Li, Yunpeng Liu, Hongqian Guo, Kehe Chen, Dahong Zhang, Gongxian Wang, Lieming Ding, Yang Wang, Xiaobin Yuan, Jun Guo
Summary: This study aimed to evaluate the efficacy of vorolanib in combination with everolimus or as monotherapy compared to everolimus alone as second-line treatment for metastatic renal cell carcinoma (RCC). The results showed that the combination of vorolanib and everolimus had a significant improvement in progression-free survival (PFS) and objective response rate compared to everolimus alone. However, there was no significant difference in PFS and objective response rate between vorolanib monotherapy and everolimus. Overall, this study offers a better treatment option for patients with metastatic RCC.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Genetics & Heredity
Wang Yangyun, Shi Guowei, Shi Shufen, Yao Jie, Yu Rui, Ren Yu
Summary: The combination of Everolimus with RSL3 or Erastin demonstrates anti-tumor effects in RCC by synergistically inhibiting cell viability and inducing ferroptosis. Inhibition of the mTOR-4EBP1 axis is crucial for the synergistic effects. Forced expression of GPX4 can abrogate ferroptosis induced by the combination treatment, suggesting a promising therapeutic option for RCC.
Article
Biochemistry & Molecular Biology
Takuro Kobayashi, Masayoshi Nagata, Yoshihiro Ikehata, Yuki Nagashima, Naoya Nagaya, Yan Lu, Shigeo Horie
Summary: We have found that the clonality of TCR repertoire is associated with the development of irAEs in RCC patients treated with ICIs. The proportion of specific sequences within the TCR repertoire is higher in patients with more severe irAEs.
CURRENT ISSUES IN MOLECULAR BIOLOGY
(2023)
Article
Health Care Sciences & Services
Kenichi Nishimura, Tatsuya Konishi, Toshiki Ochi, Ryuta Watanabe, Terutaka Noda, Tetsuya Fukumoto, Noriyoshi Miura, Yuki Miyauchi, Tadahiko Kikugawa, Katsuto Takenaka, Takashi Saika
Summary: This study found that the proportion of CD21(lo) B cells increased after combination checkpoint blockade therapy, which may be related to the occurrence of immune-related adverse events (irAEs). Patients with low baseline CD21(lo) B cell levels need closer monitoring for irAEs.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Review
Oncology
Katharina Leucht, Nalyan Ali, Susan Foller, Marc-Oliver Grimm
Summary: Immune checkpoint inhibitors, in combination with other therapeutic agents, are commonly used for the treatment of metastatic renal cancer. It is crucial to recognize and differentiate the side effects caused by these therapies for effective management.
Article
Oncology
Josiah An, Vignesh T. Packiam, Adithya Chennamadhavuni, Jordan Richards, Jayanshu Jain, Sarah L. Mott, Rohan Garje
Summary: This study assessed the incidence and survival outcomes of non-clear cell renal cell carcinoma (ccRCC) subtypes compared to ccRCC. The results showed that the survival rate was not significantly different between papillary RCC and ccRCC, while collecting duct and sarcomatoid subtypes had poorer survival outcomes. Further studies are needed to evaluate the role of neoadjuvant and adjuvant systemic therapies in improving oncologic outcomes for these subtypes.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Dylan J. Martini, Subir Goyal, Yuan Liu, Sean T. Evans, T. Anders Olsen, Katherine Case, Benjamin L. Magod, Jacqueline T. Brown, Lauren Yantorni, Greta Anne Russler, Sarah Caulfield, Jamie M. Goldman, Bassel Nazha, Wayne B. Harris, Haydn T. Kissick, Viraj A. Master, Omer Kucuk, Bradley C. Carthon, Mehmet Asim Bilen
Summary: The study revealed early onset immune-related adverse events (irAEs) are associated with significantly improved clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICIs). Specifically, endocrine irAEs, particularly thyroid irAEs, were found to significantly impact clinical outcomes. These findings suggest that irAEs, especially thyroid irAEs, may serve as clinical biomarkers of clinical outcomes in mRCC patients treated with ICIs.
Article
Nursing
Leodoro J. Labrague
Summary: This study examines the factors influencing nurses' adherence to patient safety protocols and the relationship between nurses' adherence and adverse patient events. The findings show that adherence to patient safety protocols is generally high, but the adherence rates are lower in areas such as reporting safety errors, conducting fall risk assessments, and adhering to pressure ulcer prevention guidelines. Increased adherence to safety protocols is associated with higher reporting of adverse patient events.
JOURNAL OF NURSING SCHOLARSHIP
(2023)
Article
Genetics & Heredity
Seong-Hwi Hong, Kwang-Suk Lee, Hyun-Ji Hwang, Sung-Yul Park, Woong-Kyu Han, Young-Eun Yoon
Summary: This study investigated the possibility of using a combination of everolimus and metformin as an effective treatment for RCC. The results showed that the combination treatment significantly inhibited RCC cell viability, migration, and invasion, and increased apoptosis. Transcriptome analysis revealed that the combination treatment disrupted mitochondrial dynamics. Overall, the combination of everolimus and metformin may be a novel strategy for RCC treatment by disrupting mitochondrial dynamics.
Article
Oncology
Agnese Paderi, Roberta Giorgione, Elisa Giommoni, Marinella Micol Mela, Virginia Rossi, Laura Doni, Andrea Minervini, Marco Carini, Serena Pillozzi, Lorenzo Antonuzzo
Summary: It has been found that the presence of immune-related adverse events (irAEs) is associated with better clinical response to immunotherapy. Specifically, thyroid dysfunction and skin reactions are correlated with the efficacy of immune-checkpoint inhibitors in metastatic renal cell cancer patients. Additionally, experiencing multiple irAEs in a single patient is linked to improved tumor response.
Review
Oncology
Marica Gentile, Antonella Centonza, Domenica Lovero, Raffaele Palmirotta, Camillo Porta, Franco Silvestris, Stella D'Oronzo
Summary: Breast cancer is the most common malignancy in women and can lead to skeletal metastases, causing serious complications. Identifying biomarkers that predict bone metastases risk is crucial for personalized diagnostic and therapeutic strategies. Omics sciences have played a significant role in exploring potential biomarkers for predicting bone metastases.
JOURNAL OF BONE ONCOLOGY
(2021)
Review
Oncology
Valeria Interno, Pierluigi De Santis, Luigia Stefania Stucci, Roberta Ruda, Marco Tucci, Riccardo Soffietti, Camillo Porta
Summary: Brain metastatic renal cell carcinoma is a common and poor prognostic cancer, but therapeutic advances have improved overall survival rates.
Article
Oncology
Brian A. Costello, Nrupen A. Bhavsar, Yousef Zakharia, Sumanta K. Pal, Ulka Vaishampayan, Heather Jim, Mayer N. Fishman, Ana M. Molina, Christos E. Kyriakopoulos, Che-Kai Tsao, Leonard J. Appleman, Benjamin A. Gartrell, Arif Hussain, Walter M. Stadler, Neeraj Agarwal, Russell K. Pachynski, Thomas E. Hutson, Hans J. Hammers, Christopher W. Ryan, Jack Mardekian, Azah Borham, Daniel J. George, Michael R. Harrison
Summary: The Metastatic Renal Cell Carcinoma Registry provides prospective data on real-world treatment patterns and outcomes in patients with metastatic renal cell carcinoma (mRCC). Initial findings suggest a focus on efficacy over quality of life and toxicity, indicating the need for further data and education on these endpoints.
CLINICAL GENITOURINARY CANCER
(2022)
Review
Oncology
Gaetano Pezzicoli, Francesca Moscaritolo, Erica Silvestris, Franco Silvestris, Gennaro Cormio, Camillo Porta, Stella D'Oronzo
Summary: Uterine carcinosarcoma, also known as malignant mixed M & uuml;llerian tumor, is a rare gynecological malignancy with poor prognosis. Surgical resection is the best curative option for localized disease, and additional peri-operative treatments have been shown to improve outcomes. Palliative chemotherapy is the treatment of choice for metastatic disease, with no consensus on the best regimen.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2021)
Review
Biotechnology & Applied Microbiology
Riccardo Marconcini, Gaetano Pezzicoli, Luigia Stefania Stucci, Maria Chiara Sergi, Lucia Lospalluti, Camillo Porta, Marco Tucci
Summary: Cutaneous Melanoma is an aggressive cancer with increasing incidence worldwide. The development of new drugs targeting biology and genes driving cell growth, such as BRAF targeting agents and immune checkpoint inhibitors, has improved patient outcomes. However, drug resistance remains a challenge, leading to the need for new strategies, such as combination therapies and clinical trials investigating novel ICIs.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2022)
Article
Cell Biology
Stephane Oudard, Nadine Benhamouda, Bernard Escudier, Patrice Ravel, Thi Tran, Emeline Levionnois, Sylvie Negrier, Philippe Barthelemy, Jean Francois Berdah, Marine Gross-Goupil, Cora N. Sternberg, Petri Bono, Camillo Porta, Ugo De Giorgi, Omi Parikh, Robert Hawkins, Martin Highley, Jochen Wilke, Thomas Decker, Corinne Tanchot, Alain Gey, Magali Terme, Eric Tartour
Summary: This study found that a decrease in pro-angiogenic monocyte subpopulations is associated with clinical response in mRCC patients receiving anti-angiogenic drugs. Specifically, a decrease in VEGFR-1(+)CD14 cells was correlated with longer progression-free survival and overall survival, while a decrease in Tie2(+)CD14 cells was associated with improved overall survival.
Review
Biochemistry & Molecular Biology
Davide Loizzo, Savio Domenico Pandolfo, Devin Rogers, Clara Cerrato, Nicola Antonio di Meo, Riccardo Autorino, Vincenzo Mirone, Matteo Ferro, Camillo Porta, Alessandro Stella, Cinzia Bizzoca, Leonardo Vincenti, Marco Spilotros, Monica Rutigliano, Michele Battaglia, Pasquale Ditonno, Giuseppe Lucarelli
Summary: Autophagy plays a pivotal role in the regulation of apoptosis and disease progression in prostate cancer. However, depending on the cellular context, it can have either detrimental or protective effects. Current research focuses on modulating autophagy to improve therapeutic response and chemotherapy resistance in prostate cancer, and identifying the genetic signature of autophagy as a potential means to assess aggressiveness.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Biochemistry & Molecular Biology
Nicola Antonio di Meo, Davide Loizzo, Savio Domenico Pandolfo, Riccardo Autorino, Matteo Ferro, Camillo Porta, Alessandro Stella, Cinzia Bizzoca, Leonardo Vincenti, Felice Crocetto, Octavian Sabin Tataru, Monica Rutigliano, Michele Battaglia, Pasquale Ditonno, Giuseppe Lucarelli
Summary: Metabolomic analysis has played an important role in bladder cancer research, aiding in biomarker discovery, understanding pathological behavior, and providing starting points for new diagnostic and therapeutic strategies. However, further research is needed to provide stronger evidence and make these tools feasible in clinical practice.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Health Care Sciences & Services
Romain Iaxx, Felix Lefort, Charlotte Domblides, Alain Ravaud, Jean-Christophe Bernhard, Marine Gross-Goupil
Summary: Cabozantinib is an oral tyrosine kinase inhibitor with antiangiogenic properties, which has been used as a monotherapy for metastatic renal cell cancer. With the emergence of immune checkpoint inhibitors, new standards of care involving combination treatments have been established. However, cabozantinib remains a treatment option, especially for patients who cannot receive immune checkpoint inhibitors.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT
(2022)
Article
Oncology
Ulka N. Vaishampayan, Archana Thakur, Wei Chen, Abhinav Deol, Meera Patel, Kimberlee Dobson, Brenda Dickow, Dana Schalk, Amy Schienschang, Sarah Whitaker, Amanda Polend, Joseph A. Fontana, Elisabeth I. Heath, Lawrence G. Lum
Summary: This study aimed to evaluate the safety and efficacy of the combination of HER2 bispecific antibody (HER2Bi)-armed activated T cells (HER2 BAT) and programmed death 1 inhibitor, pembrolizumab, in the treatment of metastatic castration-resistant prostate cancer (mCRPC). The results showed that this combination therapy had good safety and efficacy in mCRPC patients, indicating the need for further investigation.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Joseph W. Kim, Rana R. McKay, Marc R. Radke, Shilin Zhao, Mary-Ellen Taplin, Nancy B. Davis, Paul Monk, Leonard J. Appleman, Primo N. Lara, Ulka N. Vaishampayan, Jingsong Zhang, Asit K. Paul, Glenn Bubley, Eliezer M. Van Allen, Serhan Unlu, Ying Huang, Massimo Loda, Geoffrey I. Shapiro, Peter M. Glazer, Patricia M. LoRusso, S. Percy Ivy, Yu Shyr, Elizabeth M. Swisher, Daniel P. Petrylak
Summary: The study investigated the clinical outcomes of combining Cediranib with olaparib in patients with prostate cancer. The results showed that the combination improved radiographic progression-free survival in patients with metastatic castration-resistant prostate cancer compared to olaparib alone. However, it was also associated with a higher incidence of adverse events.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Review
Urology & Nephrology
Ben Sprangers, David E. Leaf, Camillo Porta, Maria Jose Soler, Mark A. Perazella
Summary: Immune checkpoint inhibitors (ICIs) have had a significant impact on cancer treatment, but their use can lead to immune-related adverse events, including acute kidney injury. This review provides an overview of the symptoms, biochemical markers, and potential underlying mechanisms of ICI-associated acute kidney injury, and proposes a diagnostic and management approach.
NATURE REVIEWS NEPHROLOGY
(2022)
Article
Oncology
Julius Strauss, Jean-Laurent Deville, Mario Sznol, Alain Ravaud, Marco Maruzzo, Russell K. Pachynski, Theodore S. Gourdin, Michele Maio, Luc Dirix, Jeffrey Schlom, Renee N. Donahue, Yo-Ting Tsai, XiaoZhe Wang, Yulia Vugmeyster, Frank Beier, Joerg Seebeck, Andreas Schroeder, Sarah Chennoufi, James L. Gulley
Summary: The combination of M9241 and avelumab showed good tolerability in the treatment of advanced solid tumors and urothelial carcinoma. However, the efficacy in urothelial carcinoma did not meet the predefined criterion.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Valeria Interno, Maria Chiara Sergi, Maria Elvira Metta, Michele Guida, Paolo Trerotoli, Sabino Strippoli, Salvatore Circelli, Camillo Porta, Marco Tucci
Summary: This study retrospectively analyzed the impact of clinical-pathological features and multimodal therapies on the overall survival of patients with melanoma brain metastases. The results showed that encephalic radiotherapy significantly improved survival, but not for patients with LDH levels higher than two times the upper limit normal. These findings can help guide therapeutic strategies for patients in the worst prognostic subgroup of melanoma brain metastases.
Review
Medicine, Research & Experimental
Mimma Rizzo, Patrizia Giannatempo, Camillo Porta
Summary: In recent years, advancements in diagnostic and therapeutic approaches have led to a decrease in mortality rates among patients with metastatic urothelial carcinoma. Immune checkpoint inhibitors have shown efficacy and safety in both first-line and first-line switch maintenance therapy, while targeted agents have demonstrated clinical advantages compared to standard care. Sequential treatment strategies are now feasible for patients with advanced urothelial carcinoma.
BIOLOGICS-TARGETS & THERAPY
(2021)
Article
Oncology
Diego de Miguel-Perez, Edward M. Pickering, Umberto Malapelle, William Grier, Francesco Pepe, Pasquale Pisapia, Gianluca Russo, Joseph A. Pinto, Alessandro Russo, Giancarlo Troncone, Melissa J. Culligan, Katherine A. Scilla, Ranee Mehra, Pranshu Mohindra, Oscar Arrieta, Andres F. Cardona, Marzia Del Re, Ashutosh Sachdeva, Fred R. Hirsch, Andrea Wolf, Joseph S. Friedberg, Christian Rolfo
Summary: In this study, genetic alterations in resectable pleural mesothelioma tissues and blood samples were analyzed, and it was found that high tissue tumor mutational burden, tissue median minor allele frequency, blood tumor mutational burden, and specific mutations were correlated with outcomes in patients with resected PM. These findings suggest that molecular profiling could help identify longer survivors in patients with resected PM.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Davide Melisi, Camilla Zecchetto, Valeria Merz, Giuseppe Malleo, Luca Landoni, Alberto Quinzii, Simona Casalino, Federica Fazzini, Marina Gaule, Camilla Pesoni, Luca Casetti, Alessandro Esposito, Giovanni Marchegiani, Cristiana Piazzola, Mirko D'Onofrio, Riccardo de Robertis, Armando Gabbrielli, Laura Bernardoni, Stefano F. Crino, Silvia Pietrobono, Claudio Luchini, Camillo Aliberti, Guido Martignoni, Stefano Milleri, Giovanni Butturini, Aldo Scarpa, Roberto Salvia, Claudio Bassi
Summary: This study evaluated the safety and activity of liposomal irinotecan in the perioperative treatment of resectable pancreatic ductal adenocarcinoma (rPDAC) patients. The results showed that NALIRIFOX has manageable and active outcomes, and should be further investigated in randomized trials comparing it to standard upfront surgery followed by adjuvant therapy.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Eric Jonasch, Todd M. Bauer, Kyriakos P. Papadopoulos, Elizabeth R. Plimack, Jaime R. Merchan, David F. Mcdermott, M. Dror Michaelson, Leonard J. Appleman, Ananya Roy, Rodolfo F. Perini, Yanfang Liu, Toni K. Choueiri
Summary: After a median follow-up of 41.2 months, belzutifan monotherapy demonstrated durable antitumor activity in patients with advanced ccRCC and acceptable safety.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Patricia A. H. Hamers, Geraldine R. Vink, Marloes A. G. Elferink, Leon M. G. Moons, Cornelis J. A. Punt, Anne M. May, Miriam Koopman
Summary: Screen-detection of the primary tumor is associated with longer overall survival after metachronous metastasis.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Camilla Nero, Nicolo Bizzarri, Stefano Di Berardino, Francesca Sillano, Giuseppe Vizzielli, Francesco Cosentino, Virginia Vargiu, Pierandrea De Iaco, Anna Myriam Perrone, Enrico Vizza, Benito Chiofalo, Stefano Uccella, Fabio Ghezzi, Luigi Carlo Turco, Giacomo Corrado, Diana Giannarelli, Tina Pasciuto, Gian Franco Zannoni, Anna Fagotti, Giovanni Scambia
Summary: This study evaluates the sensitivity and specificity of sentinel-lymph-node mapping compared to systematic lymphadenectomy in detecting lymph node metastasis in early stage ovarian cancer. The results show that sentinel-lymph-node mapping did not reach the expected sensitivity, but ultra-staging protocol improved the accuracy of diagnosis for patients.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Adriana Hepner, Judith M. Versluis, Roslyn Wallace, Clara Allayous, Lauren Julia Brown, Claudia Trojanielloh, Camille Lea Gerardi, Yanina J. L. Jansenj, Prachi Bhave, Bart Neyns, Andrew Haydon, Olivier Michielin, Joanna Manganan Oliver Klein, Alexander N. Shoushtari, Allison Betof Warner, Paolo Antonio Ascierto, Jennifer Leigh McQuade, Matteo S. Carlino, Lisa Zimmer, Celeste Lebbe, Douglas B. Johnson, Shahneen Sandhu, Victoria Atkinson, Christian U. Blank, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies
Summary: Acquired resistance to PD-1 therapy in melanoma is mainly oligometastatic, and patients may have a favorable survival outcome following salvage treatment.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Savannah Roy, Stephanie Lakritz, Anna R. Schreiber, Elizabeth Molina Kuna, Cathy J. Bradley, Lavanya Kondapalli, Jennifer R. Diamond
Summary: This study evaluates major adverse cardiovascular events (MACE) in older women with TNBC treated with anthracycline and taxane-based chemotherapy (ATAX) compared to taxane-based chemotherapy (TAX). The results show that ATAX does not increase the risk of MACE and there is no difference in survival between patients who received TAX and ATAX.
EUROPEAN JOURNAL OF CANCER
(2024)
Letter
Oncology
Pei-Chun Weng, Yau-Li Huang, Chun-Yu Cheng
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Philipp Jansen, Jean Le 'Clerc Arrastia, Daniel Otero Baguer, Maximilian Schmidt, Jennifer Landsberg, Joerg Wenzel, Michael Emberger, Dirk Schadendorf, Eva Hadaschik, Peter Maass, Klaus Georg Griewank
Summary: This study highlights the enormous potential of artificial intelligence in pathology, showing that it can aid in the identification of rare cutaneous adnexal tumors and potentially become a standard tool in routine diagnostics.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Casper W. F. van Eijck, Gaby Strijk, Eveline E. Vietscha, Fleur van der Sijde, Maaike Verheij, Dana A. M. Mustafa, Madelief Vinkc, Joachim G. J. V. Aerts, Casper H. J. van Eijck, Marcella Willemsen
Summary: The study reveals that FOLFIRINOX has immunomodulatory effects, suggesting its potential in immune-based combination therapies for pancreatic cancer. Additionally, certain plasma proteins hold promise as circulating predictive biomarkers for early prediction of FOLFIRINOX response in patients with pancreatic cancer.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Marwan Fakih, Chongkai Wang, Jaideep Sandhu, Jian Ye, Colt Egelston, Xiaochen Li
Summary: This study explores the impact of metastatic sites on treatment outcomes for chemotherapy-refractory colorectal cancer patients. It found that patients with liver or peritoneal metastases had poor treatment outcomes, while those with lung-only metastases showed significant response. The presence of concurrent lymph node or other extrahepatic metastatic disease diminished treatment response in patients with lung metastases. Future checkpoint inhibitor trials should stratify patients based on metastatic locations.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Georgios Christos Tsiatsianis, Candace S. Y. Chan, Ioannis Mouratidis, Nikol Chantzi, Anna Maria Tsiatsiani, Nelson S. Yee, Apostolos Zaravinos, Verena Kantere, Ilias Georgakopoulos-Soares
Summary: The study reveals that nullpeptides can serve as biomarkers for cancer detection and treatment, particularly in highly recurrent cancer patients. These nullpeptides primarily occur in highly expressed genes, particularly in specific loci of oncogenes and tumor suppressors. Recurrent nullpeptides are more likely to be found in neoantigens, which play a significant role in immunotherapy.
EUROPEAN JOURNAL OF CANCER
(2024)